Parallax Volatility Advisers
TBPH icon

Parallax Volatility Advisers’s Theravance Biopharma TBPH Stock Holding History

Parallax Volatility Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-338,848
Closed -$5.53M – 3418
2019
Q2 		$5.53M Buy
338,848
+258,005
+319% +$5.23M 0.01% 694
2019
Q1 		$1.83M Buy
+80,843
New +$2.05M ﹤0.01% 1031
2018
Q1 		– Sell
-6,384
Closed -$178K – 4112
2017
Q4 		$178K Buy
+6,384
New +$189K ﹤0.01% 2372

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Parallax Volatility Advisers's TBPH Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Theravance Biopharma (TBPH) in Q3 2019, closing a stake of 338,848 shares — an estimated $5.53M sold.

Parallax Volatility Advisers first reported a position in TBPH in Q4 2017 and held it in 3 quarters. The position peaked at $5.53M in Q2 2019. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

  • Parallax Volatility Advisers reported no remaining Theravance Biopharma position as of Q3 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 338,848 Theravance Biopharma shares in Q3 2019, an estimated $5.53M.
  • Parallax Volatility Advisers first reported a position in Theravance Biopharma in Q4 2017 and held it in 3 quarters.
  • Parallax Volatility Advisers's Theravance Biopharma position peaked at $5.53M in Q2 2019.
  • 92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.